LDI has sold UltiMed to Levine Leichtman Capital Partners

UltiMed, Inc., a portfolio company of LDI, Ltd., has been sold to an investment vehicle sub-managed by Levine Leichtman Capital Partners, LLC.

UltiMed’s insulin pen needles, syringes and complementary products are critical offerings for diabetes patients who need daily insulin injections and for companion animals who increasingly suffer from this life-threatening disease. UltiMed’s proprietary “dispense and dispose” solutions provide diabetes patients a safe and convenient way to store used sharps following injection.

Levine Leichtman Capital Partners is a private equity and venture capital firm specializing in acquisitions, buyouts, recapitalizations, refinancing, balance sheet restructuring, growth financing, structured equity, distressed debt, leveraged loan and mezzanine investments in the middle market.

LDI, Ltd. is a private equity firm specializing in investing in acquisitions and add-on acquisitions. It is a family office based in Indianapolis, IN, with more than a century of experience funding and operating high-potential, middle-market companies.

One of Oaklins’ teams in the USA served as the exclusive financial advisor to UltiMed, Inc., a portfolio company of LDI, Ltd., in this transaction.

Service

M&A sell-side

Parties

“We selected the team based on their prior experience with UltiMed and their expertise in transactions in the diabetes and animal health sectors. They did an outstanding job of presenting UltiMed’s many strengths and growth opportunities to the market, and their deep relationships with potential acquirors were key to our success. We particularly appreciate the senior team focus they brought to completing this transaction despite the emergence of the COVID-19 pandemic in the midst of this assignment.”

John Martin

VP Corporate Development, LDI, Ltd.

Talk to the deal team

Michael S. Goldman

Managing Director

New York, United States
Oaklins TM Capital

View profile Get in touch

Steve Hunter

Managing Director

Atlanta, United States
Oaklins TM Capital

View profile Get in touch

James McLaren

Managing Director

New York, United States
Oaklins TM Capital

View profile Get in touch

John Dean

Associate Director

Atlanta, United States
Oaklins TM Capital

View profile Get in touch

Related deals

STM Environmental has been acquired by Phenna Group

Private Equity | Business Support Services

STM Environmental has been acquired by Phenna Group

STM Environmental has been acquired by Phenna Group, gaining access to a broader network of expertise, enhanced resources and global reach. With extensive experience in life safety, environmental compliance and quality testing, along with a wide client base, Phenna Group is the ideal partner to accelerate STM Environmental’s expansion.

Learn more

Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.

Healthcare

Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.

Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.

Learn more

Acapo AS has been acquired by Longship AS

Private Equity | Business Support Services

Acapo AS has been acquired by Longship AS

Oslo-based intellectual property advisory firm Onsagers, supported by Longship since May 2024, has acquired Acapo AS. By combining decades of expertise and global reach, this strategic acquisition unites two of Norway’s most reputable IP firms, enabling them to offer a comprehensive range of solutions in patents, trademarks and IP strategy. This milestone strengthens their position in building a best-in-class network for strategic IP management, marking a key step in their continued growth.

Learn more